Atherosclerosis
Volume 197, Issue 2 , Pages 515-523 , April 2008

Inhibition of non-Ras protein farnesylation reduces in-stent restenosis

  • Paul Coats
    • ,
  • Simon Kennedy

      Affiliations

    • Present address: Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
    • ,
  • Susan Pyne
    • ,
  • Cherry L. Wainwright

      Affiliations

    • Present address: School of Pharmacy, The Robert Gordon University, Aberdeen AB10 1FR, UK.
    • ,
  • Roger M. Wadsworth

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 141 548 2154; fax: +44 141 552 2562.

Received 28 March 2007 ,Revised 11 June 2007 ,Accepted 19 June 2007.

References 

  1. Indolfi C, Avvedimento EV, Rapacciuolo A, et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1995;1:541–545
  2. Wu CH, Lin CS, Hung JS, et al. Inhibition of neointimal formation in porcine coronary artery by a Ras mutant. J Surg Res. 2001;99:100–106
  3. Ehrhardt A, Ehrhardt GRA, Guo X, Schrader J.W. . Ras and relatives—job sharing and networking keep an old family together. Exp Hematol. 2002;30:1089–1106
  4. Lane KT, Beese L.S. . Structural biology of protein farnesyltransferase and geranylgeranlytransferase type 1. J Lipid Res. 2006;47:681–699
  5. Basso AD, Mirza A, Liu G, et al. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTor signalling. J Biol Chem. 2005;280:31101–31108
  6. Hussein D, Taylor SS. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci. 2002;115:3403–3414
  7. Basso AD, Kirschmeier P, Bishop WR. Farnesyl transferase inhibitors. J Lipid Res. 2006;47:15–31
  8. Work LM, McPhaden AR, Pyne NJ, et al. Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty. Circulation. 2001;104:1538–1543
  9. Chemla E, Castier Y, Julia P, et al. Inhibition of intimal hyperplasia by an antisense oligonucleotide if farnesyl transferase delivered endoluminally during iliac angioplasty in a rabbit model. Ann Vasc Surg. 1997;11:581–587
  10. Crul M, de Klerk GJ, Beijnen JH, Schellens JHM. Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs. 2001;12:163–184
  11. Manne V, Ricca CS, Brown JG, et al. Ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. Drug Dev Res. 1995;34:121–137
  12. Flaherty JD, Davidson CJ. Diabetes and coronary revascularisation. JAMA. 2005;293:1501–1508
  13. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronaray vasoconstriction. J Am Coll Cardiol. 2005;46:231–236
  14. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors and outcomes of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  15. Schwartz RS, Edelman ER. Drug-eluting stents in preclinical studies: recommended evaluation from a Consensus Group. Circulation. 2002;106:1867–1873
  16. Sambi BS, Hains MD, Waters CM, et al. The effect of RGS12 on PDGFbeta receptor signalling to p42/p44 mitogen activated protein kinase in mammalian cells. Cell Signal. 2006;18:971–981
  17. Kennedy S, McPhaden AR, Wadsworth RM, Wainwright CL. Correlation of leukocyte adhesiveness, adhesion molecule expression and leukocyte-induced contraction following balloon angioplasty. Br J Pharmacol. 2000;130:95–108
  18. Van Belle E, Maillard L, Tio FO, Isner JM. Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation. Biochem Biophys Res Commun. 1997;235:311–316
  19. Malik N, Gunn J, Holt CM, et al. Intravascular stents: a new technique for tissue processing for histology, immunohistochemistry, and transmission electron microscopy. Heart. 1998;80:509–516
  20. Gunn J, Arnold N, Chan KH, et al. Coronary artery stretch versus deep injury in the development of in-stent neointima. Heart. 2002;88:401–405
  21. Kennedy S, Wadsworth RM, Wainwright CL. Effect of antiprolifetative agents on vascular function in normal and in vitro balloon injured porcine coronary arteries. Eur J Pharmacol. 2003;481:101–107
  22. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131–137
  23. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem. 1998;273:19925–19928
  24. Miller AM, McPhaden AR, Wadsworth RM, Wainwright CL. Inhibition by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of restenosis. Cardiovasc Res. 2001;49:838–850
  25. Cuda G, Paterno R, Ceravolo R, et al. Protection of human endothelial cells from oxidative stress—role of Rasd-ERK1/2 signalling. Circulation. 2002;105:968–974

PII: S0021-9150(07)00392-9

doi: 10.1016/j.atherosclerosis.2007.06.007

Atherosclerosis
Volume 197, Issue 2 , Pages 515-523 , April 2008

Article Tools

* Image Usage & Resolution